1.Large molecular size and negative surface charge: mRNA molecules possess high molecular weights and carry dense negative surface charges. Human cell membranes are phospholipid bilayers that also bear negative charges; electrostatic repulsion prevents bare mRNA from crossing cell membranes at all.
2.Circulating nucleases as molecular “shredders”: Blood and interstitial fluids are abundant in nucleases. Unencapsulated mRNA injected into circulation undergoes rapid degradation within minutes and is readily engulfed by immune cells as foreign matter.
01 Four Core Components: The Four Cornerstones of the Nanoscale Barrier
- Ionizable cationic lipid (core component: nucleic acid binding and controlled intracellular release)
- PEGylated lipid (outer shell: particle size regulation, anti-aggregation, prolonged systemic circulation)
- Cholesterol (scaffold: gap filling, membrane fluidity modulation, structural stabilization)
- Helper phospholipid (auxiliary agent: facilitating cellular uptake and endosomal escape)
1. Ionizable Cationic Lipids: The Core Mediator of Controlled Release
- First generation: Permanently cationic lipids (e.g., DOTMA, DOTAP). These maintain constant positive charges, enabling efficient mRNA complexation in vitro, yet they exhibit severe cytotoxicity in vivo and readily bind serum proteins, leading to rapid clearance and loss of activity.
- Second generation: pH-sensitive ionizable lipids with adaptive charge properties. Their ingenious design enables charge switching based on environmental pH. At physiological blood pH (~7.4), the lipids remain neutral, evading immune clearance and extending circulatory half-life. Upon cellular internalization into acidic endosomes (pH < 6.0), they undergo protonation to acquire positive charges, triggering fusion with the anionic endosomal membrane and subsequent cytoplasmic release of mRNA.
- Third generation: Biodegradable, high-transfection, target-customizable lipids. To address systemic accumulation and toxicity observed with second-generation lipids, ester linkages are embedded within the carbon backbones of third-generation lipids, which are rapidly cleaved by intracellular esterases to shorten plasma retention. Advanced third-generation ionizable lipids engineered with cyclic headgroups or specialized polar moieties can activate immune signaling cascades (e.g., the STING pathway) to potentiate anti-tumor immunity. Furthermore, they can be selectively targeted to cardiomyocytes, macrophages or T cells; when loaded with antimicrobial peptides or therapeutic enzymes, they directly eliminate drug-resistant bacteria and mitigate sepsis.
2. PEGylated Lipids (PEG-Lipids): Nanoscale Circulation Regulators
- Particle size modulator: PEG lipid concentration directly dictates final LNP diameter during self-assembly; higher PEG loading yields smaller nanoparticles.
- Steric anti-aggregation barrier: The hydrophilic PEG corona generates steric hindrance during storage, inhibiting spontaneous particle fusion and agglomeration.
- The “PEG dilemma” and shedding mechanism: Persistent surface PEG chains impede LNP attachment to target cell membranes. Critically, PEG-lipids gradually dissociate from the LNP surface during systemic circulation. This programmable shedding mechanism preserves circulatory stability while removing steric barriers proximal to target cells to facilitate endocytosis.
3. Cholesterol: Nanostructural Scaffold and Stabilizer
- Modulation of membrane rigidity and fluidity: Its characteristic sterane ring restricts excessive lipid bilayer motion, enhancing membrane integrity and preventing leakage of encapsulated mRNA.
- Promotion of membrane fusion: Cholesterol lowers the transition temperature required for bilayer-to-hexagonal phase rearrangement upon cellular uptake, drastically accelerating cytoplasmic mRNA release.
4. Helper Phospholipids: Endocytosis-Promoting Scaffolds
02 Physicochemical Properties: Key Parameters Governing LNP In Vivo Fate
1.Particle Size and Specific Surface Area
For vaccine applications, LNPs with a diameter of approximately 50 nm consistently deliver optimal delivery performance regardless of lipid formulation. Reduced particle size exponentially amplifies relative surface area, boosting reactivity with the biological microenvironment. Particle diameter directly determines the feasibility of cellular uptake via endocytosis.
2.Surface Charge and pKa Value
Surface charge represents the primary determinant of LNP biodistribution and biosafety. The pKa of ionizable lipids—the pH at which half the lipid population undergoes protonation and acquires positive charge—is a critical design metric. For intravenously administered LNPs, the optimal pKa range of core ionizable lipids falls between 6.2 and 6.6, ensuring neutrality in systemic blood and rapid protonation within acidic endosomes.
3.Morphology and Surface Composition
Spherical nanoparticles undergo far more efficient cellular endocytosis compared to irregularly shaped counterparts, whereas non-spherical particles exhibit altered fluid drift kinetics within capillaries. Microfluidic manufacturing enables precise tuning of LNP global morphology and surface composition (e.g., PEG chain length, lipid anchor alkyl chain length) to accurately modulate systemic circulation half-life.
03 From Cellular Uptake to Intracellular Release: The Nine-Step Pharmacological Journey of mRNA-LNPs
1.Systemic Delivery to Target Tissues: LNPs encapsulate and shield mRNA core from enzymatic degradation upon entering the body.
2.Cellular Adhesion: LNPs bind to adjacent muscle cells or professional antigen-presenting cells (APCs), including dendritic cells and macrophages, at the injection site.
3.Endocytic Internalization: Plasma membrane invagination engulfs LNPs into membrane-bound intracellular vesicles termed endosomes.
4.Endosomal Escape (Rate-Limiting Step): Acidification of the endosomal lumen triggers rapid protonation of ionizable lipids, which interact electrostatically with the anionic endosomal membrane to induce membrane disruption and fusion. mRNA escapes intact into the cytosol.
5.In Situ Protein Translation: Cytosolic ribosomes bind the delivered mRNA and translate it into target pathogen antigen proteins.
6.Antigen Processing: Synthesized antigens follow two divergent fates: a portion is secreted extracellularly, while intracellular antigens are degraded into immunodominant epitopes via proteasomal cleavage.
7.Cellular Immunity Priming (MHC Class I Pathway): Processed antigen epitopes complex with cell-surface MHC I molecules, which are recognized by CD8+ T cells to generate cytotoxic T lymphocytes.
8.Helper Immune Activation (MHC Class II Pathway): Extracellular secreted antigens are phagocytosed by neighboring APCs, presented via MHC II complexes to CD4+ helper T cells that coordinate central immune signaling.
9.Neutralizing Antibody Production: Free circulating antigens are directly recognized by B cells. Assisted by helper T cell signaling, B cells undergo clonal expansion and differentiation to secrete abundant antigen-specific neutralizing antibodies, establishing a humoral defense barrier against native viral invasion.
04 Conclusion: Democratizing Access to Gene Therapy
